Whole-Body Integrated [
Aged
Aged, 80 and over
Antigens, Surface
/ metabolism
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Glutamate Carboxypeptidase II
/ metabolism
Humans
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Multimodal Imaging
/ methods
Neoplasm Recurrence, Local
/ diagnostic imaging
Oligopeptides
/ chemistry
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
/ methods
Prostatectomy
/ methods
Prostatic Neoplasms
/ diagnostic imaging
Radiopharmaceuticals
/ chemistry
Reference Standards
Tissue Distribution
Whole Body Imaging
/ methods
PSA relapse
Recurrent prostate cancer
Whole-body MRI staging
[68Ga]PSMA-11 PET/MRI
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
5
9
2019
medline:
3
6
2021
entrez:
5
9
2019
Statut:
ppublish
Résumé
The aim of this study was to evaluate the detection rate of [ A total of 93 patients with biochemically recurrent prostate cancer underwent [ PC relapse was detected in 62/93 patients. PET/MRI detected 148 out of 150 lesions described in PET/CT. In addition, PET/MRI detected 11 lesions not detected in PET/CT (5 lymph nodes, 6 local recurrences). The exact McNemar statistical test (one-sided) showed significant difference between PET/CT and PET/MRI for diagnosis of local recurrence (p value = 0.031). Diagnostic confidence for (iii) was higher in PET/MRI compared with PET/CT (PET/CT = 1.1; PET/MRI = 4.9). Diagnostic confidence for (i) (PET/CT = 4.9; PET/MRI = 4.6), (ii) (PET/CT = 4.9; PET/MRI = 4.6), and (iv) (PET/CT = 4.6; PET/MRI = 4.8) was equivalent between PET/MRI and PET/CT. Integrated [
Identifiants
pubmed: 31482413
doi: 10.1007/s11307-019-01424-4
pii: 10.1007/s11307-019-01424-4
doi:
Substances chimiques
Antigens, Surface
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
788-796Références
Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, Kattan MW (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715–717
doi: 10.1093/jnci/djj190
Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163:1632–1642
doi: 10.1016/S0022-5347(05)67511-8
Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20:3376–3385
doi: 10.1200/JCO.2002.01.150
Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352–3359
doi: 10.1200/JCO.2000.18.19.3352
Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, Leibel S, Scardino PT (2001) Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58:393–399
doi: 10.1016/S0090-4295(01)01233-X
Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21:4568–4571
doi: 10.1200/JCO.2003.05.046
NCCN Guidelines Version 3.2018 Prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf ; accessed 07.07.2018
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M (2014) Comparison of PET/CT and PET/MRI hybrid systems using a
doi: 10.1007/s00259-013-2660-z
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET/CT imaging with the
doi: 10.1007/s00259-014-2949-6
Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Asfhar-Oromieh A, Herrmann K, Eiber M (2017) PSMA ligands for PET imaging of prostate cancer. J Nucl Med 58:1545–1552
doi: 10.2967/jnumed.117.191031
Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive
doi: 10.1016/j.eururo.2016.06.021
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K (2017)
doi: 10.1007/s00259-017-3670-z
Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, Bonekamp D, Kopka K, Eder M, Heusser T, Kachelriess M, Wieczorek K, Sachpekidis C, Flechsig P, Giesel F, Hohenfellner M, Haberkorn U, Schlemmer HP, Dimitrakopoulou-Strauss A (2017) Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in
doi: 10.1007/s00259-016-3594-z
Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A (2016) Comparison of hybrid (68)Ga-PSMA PET/MRI and
doi: 10.1007/s00259-015-3206-3
Lütje S, Cohnen J, Gomez B, Grüneisen J, Sawicki L, Rübben H, Bockisch A, Umutlu L, Pöppel TD, Wetter A (2017) Integrated
doi: 10.3413/Nukmed-0850-16-09
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T (2016) Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70:829–836
doi: 10.1016/j.eururo.2015.12.053
Kitajima K, Hartman R, Froemming A et al (2015) Detection of local recurrence of prostate cancer after radical prostatectomy using endorectal coil MRI at 3 T: addition of DWI and dynamic contrast enhancement to T2-weighted MRI. AJR Am J Roentgenol 205:807–816
doi: 10.2214/AJR.14.14275
Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mège-Lechevallier F, Colombel M, Rouvière O (2013) Influence of imaging and histological factors on prostate cancer detection and localization on multiparametric MRI: a prospective study. Eur Radiol 23:2019–2029
doi: 10.1007/s00330-013-2795-0
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 59:469–478
doi: 10.2967/jnumed.117.198119
Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, Kraff O, Forsting M, Lauenstein TC, Umutlu L (2015) [
doi: 10.1007/s00259-014-2902-8
Domachevsky L, Bernstine H, Goldberg N, Nidam M, Stern D, Sosna J, Groshar D (2017) Early
doi: 10.1016/j.crad.2017.06.116
Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Altenbernd JC, Schlosser T, Bockisch A, Pöppel T, Lauenstein T, Nagarajah J (2014) Evaluation of the PET component of simultaneous [
doi: 10.1007/s00259-013-2560-2
Spick C, Herrmann K, Czernin J (2016)
doi: 10.2967/jnumed.115.158808
Heußer T, Mann P, Rank CM, Schäfer M, Dimitrakopoulou-Strauss A, Schlemmer HP, Hadaschik BA, Kopka K, Bachert P, Kachelrieß M, Freitag MT (2017) Investigation of the halo-artifact in
doi: 10.1371/journal.pone.0183329
pubmed: 28817656
pmcid: 5560715
Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M (2018)
doi: 10.2967/jnumed.117.204677
Ruijter ET, van de Kaa CA, Schalken JA et al (1996) Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180:295–299
doi: 10.1002/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W